English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mycophenolate mofetil (MMF) is a drug that is commonly used as a post-transplant immunosup-pressive agent. The mechanism of action of MMF is via non-competitive, reversible inhibition of inosine monophosphate dehydrogenase (IMPDH). IMPDH is required for purine synthesis during lymphocyte activation w1x. Although effective for treating allograft rejection w2±5x, MMF has well known side effects including gastrointestinal upset, lymphopenia, and the risk of opportunistic infections w6±7x. Hepatotoxicity and nephrotoxicity are not common w8x. The factor V Leiden mutation involves a single adenine-for-guanine mutation at position 506, ®rst described in 1993 w9±10x. Mutated factor V is resistant to degradation by activated protein C, predisposing patients to thrombosis w9x. In this paper, we describe a case of proven deep venous thrombosis (DVT) in a 62-year-old cadaveric renal transplant recipient several days after starting MMF. The MMF was administered on two separate occasions, several months apart, and 4 years post-transplant because of episodes of chronic allograft nephropathy (CAN). The patient developed a DVT soon after receiving the MMF on both occasions. A haematological investigation revealed that the patient (P.F.) was heterozygous for factor V Leiden. The timing and reproducible relationship between the administration of MMF and the development of DVT strongly suggest a causal relationship between the drug and the occurrence of thrombosis. In this paper we describe what we think is a rare case of DVT as a complication of MMF. Case P.F. is a 62 year-old woman who was diagnosed with primary membranous glomerulonephritis in 1992. Her renal function declined and by March 1995 she required peritoneal dialysis. On 25 July 1995 the patient underwent a right-sided cadaveric renal transplant. An ultrasound performed prior to discharge revealed a normal transplant kidney. Her creatinine decreased from a pre-operative level of 586 mmolul to 78 mmolul by the time of discharge. Her discharge medications included cyclosporine A micro-immulsion 100 mg PO bid, azathioprine, and a tapering dose of prednisone. The patient's post-operative course was uneventful except for a nasal abscess, and the development of type 2 diabetes mellitus secondary to her immuno-suppressive medications. Her creatinine stabilized at 130±135 mmolul until April 1999, when her creatinine was noted to be 160 mmolul, and continued to increase slowly, reaching 236 mmolul by the beginning of June 1999. A renal biopsy that was performed 7 June 1999 demonstrated CAN, Grade III, with features of chronic transplant glomerulopathy and severe inter-stitial ®brosis. There was no evidence of membranous …

Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden